Berdazimer sodium, sold under the brand name Zelsuvmi, is a medication used for the treatment for molluscum contagiosum.

[3] The most common side effects occurred at the drug application site including pain, rash, itch, eczema, swelling, erosion, discoloration, blister, irritation, and infection.

[1] The US Food and Drug Administration (FDA) approved berdazimer sodium based on evidence from three clinical trials (NI-MC301, NI-MC302, and NI-MC304) of 1,598 participants with molluscum contagiosum.

[2] Efficacy was assessed as the proportion of participants achieving complete clearance at week twelve.

[2] Complete clearance was defined as the subject having a total of molluscum contagiosum lesion count of zero at assessment.